BinaxNOW™ COVID-19 Ag Card Home Test and NAVICA™ App

At-home COVID-19 antigen testing provides rapid results in the safety and convenience of your home

The 15-minute BinaxNOW™ COVID-19 Ag Card Home Test has received FDA Emergency Use Authorization for at-home testing in collaboration with eMed, a digital health solution. This first-of-its kind service for COVID-19 testing prescribes and ships the test directly to your home. A trained telehealth professional then guides you through the at-home self-test via video call using the BinaxNOW COVID-19 Ag Card Home Test and Abbott’s complementary NAVICA™ mobile app to enable the testing process and display BinaxNOW COVID-19 test results.

Prescription home use. Only available in the US.

Benefits

BinaxNOW COVID-19 Ag Card Home Test

A Breakthrough Rapid Antigen Test

Simple test procedure using a nasal swab and a test the size of a credit card
Read results in 15 minutes
Detects active COVID-19 infection
Intended for individuals suspected of COVID-19 within the first seven days of symptom onset

NAVICA Mobile App

Designed To Restore Confidence In Daily Life

When you download the NAVICA mobile app to your smartphone or tablet, you will be able to:

Display your COVID-19 test result and review previously stored COVID-19 test results
Receive an encrypted, digital NAVICA Pass with a negative test result, similar to an airline boarding pass
Share your NAVICA Pass with NAVICA-enabled organizations such as employers and schools to verify your negative COVID-19 test results

eMed Digital Health Solution

Your Guide To At-Home Testing

Provides a digital platform for fast, easy and affordable at-home COVID-19 testing
Includes certified guides to direct and supervise testing via video call

Helpful Documents

References

Google Play and the Google Play Logo are trademarks of Google LLC.
App Store and the Apple Logo are trademarks of Apple Inc.

The BinaxNOW™ COVID-19 Ag Card Home Test has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization. The test has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.